BP 101 - Ovoca Bio
Alternative Names: BP101Latest Information Update: 08 Jan 2021
Price :
$50 *
At a glance
- Originator Ivix
- Developer Ovoca Bio
- Class Antibacterials; Beta-lactams; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Female sexual dysfunction
Highest Development Phases
- Preregistration Female sexual dysfunction
Most Recent Events
- 05 Jan 2021 Ovoca Bio plans a phase II dose-ranging study for Female sexual dysfunction in New Zealand and Australia (Intranasal)
- 04 Jan 2021 Phase-II clinical trials in Female sexual dysfunction in Australia (Intranasal) (ACTRN12620001356954)
- 04 Jan 2021 Phase-II clinical trials in Female sexual dysfunction in New Zealand (Intranasal) (ACTRN12620001356954)